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ABSTRACT 
 
Angiogenesis and Myogenesis in a Chronic Ischemic Heart 
 
by 
Esha Ibrahim 
 
Miniswine underwent procedures to evaluate treating chronic ischemia with the implantation of 
autologous satellite cells and laser transmyocardial revascularization (TMR).  The objective was 
to combine two therapies to restore cardiac function. This experiment involved three surgical 
procedures:  (1) placing a constrictor on the coronary artery; (2) producing channels and  
implanting cells; (3) obtaining samples. The swine were divided into groups: Group 1, Ischemia; 
Group 2, Ischemia + Laser TMR; Group 3, Ischemia + Laser TMR+ Cells; Group 4, Ischemia + 
Cells.   Sonomicrometry and Millar pressure transducers were used to determine contractility, left 
ventricular pressure, and pressure-volume loops. There were no significant differences (p<0.05) 
among the hemodynamic data except for Group 4, which produced significantly lower output 
values.  Morphological evaluation revealed a significantly reduced scar area in Group 3. Although 
there was a significant difference in scar area, the phenomena behind this improvement as 
compared to the unimproved hemodynamic function is not understood.  
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CHAPTER 1 
INTRODUCTION 
 
Despite a significant advance in its prevention and treatment, coronary artery disease 
(CAD) remains the leading cause of death. According to the American Heart Association, nearly 
13 million people in the United States suffer from some form of CAD.  CAD is the most 
significant chronic condition and the leading cause of death for all segments of society.  
Conventional treatment for the disease includes medical therapies to reduce the risk factors, to 
reduce myocardial oxygen consumption, and to prevent progression of the disease; and 
interventional therapies are intended to restore the coronary artery blood flow either by 
angioplasty or surgery bypass (Braunwald 1997).  These approaches, however, are limited by the 
development over time of native vessel narrowing and graft occlusions.  There are a growing 
number of patients suffering from angina who, despite continued technical advances, cannot be 
treated by these conventional therapies.  Accordingly, there is interest in exploring alternative 
forms of therapy to ameliorate angina symptoms and improve blood flow to ischemic 
myocardium.  Transmyocardial revascularization is a newly-developed surgical treatment for 
patients with symptomatic end-stage coronary artery disease who are not candidates for 
conventional revascularization.  Although it is still unresolved as to how laser transmyocardial  
revascualrization achieves therapeutic effects, a growing amount of clinical and experimental 
evidence suggests that laser transmyocardial revascularization-induced angiogenesis plays an 
important role in this therapeutic approach. 
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Transmyocardial Revascularization (TMR)  
  Transmyocardial Revascularization (TMR) is a fairly new alternative treatment for 
patients with advanced coronary disease whose anatomy is not amenable to percutaneous 
coronary intervention or conventional coronary artery bypass graft surgery (CABG) (Allen et al. 
2004).  During TMR, small channels, or holes, are created in the heart via a laser device applied 
to the myocardial surface (See Figure 1).  
 
Figure 1. Laser Hand-piece in Contact with Myocardium (PLC Medical Systems, Milford, MA) 
 
The concept was based on the ability to achieve adequate myocardial perfusion by the creation of 
direct transmural channels through the ventricle.  It is thought, as Figure 2 portrays, that the 
injury produced by the laser energy may result in the elaboration of vascular growth factors that 
stimulate angiogenesis (Horvath 2004a). 
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Figure 2.  Illustration showing a Proposed Mechanism for TMR Effectiveness 
(PLC Medical Systems, Milford, MA) The injury to the myocardium elicited by the laser is 
thought to generate angiogenesis indirectly. 
 
The application of TMR into clinical practice has been rapid and potentially driven by 
multiple factors.   First, TMR represents one of the few existing treatment options for patients 
experiencing angina who do not qualify as candidates for traditional revascularization (Horvath 
2004).  In these patients, clinical trials have shown that TMR provided favorable symptomatic 
effect in many patients.  Lastly, TMR requires little additional educational or technical training to 
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administer and commands professional fees similar to those required for traditional bypass surgery 
(Abo-Auda and Benza 2003). 
It has been demonstrated that transmyocardial laser channels failed to acutely increase 
regional myocardial blood flow (Lutter and Yoshitake 1998).  However, laser TMR is still being 
used to treat patients with diffuse coronary artery disease who are not amenable to conventional 
procedures (Samuels et al. 2004).  The clinical experience with laser TMR indicates that angina is 
significantly relieved, perfusion and treadmill tolerance improved, and hospital admissions are 
decreased.  The mechanism which facilitates reported laser TMR-related improvements remains 
something of a mystery.   
 
Angiogenesis Hypothesis. 
Several experimental studies have shown increases in vascularization which supports the 
angiogenesis hypothesis as an explanation for the unexplained phenomena behind Transmyocardial 
Revascularization. These studies have used a variety of methods to  create the transmural 
channels: needles, variety of lasers, radio frequency energy, and growth factors.  Nearly all 
devices investigated for TMR have succeeded in inducing angiogenesis in some form.  Therefore, 
many investigators believe that angiogenesis could just be part of the normal healing process 
following myocardial injury. 
Perfusion analysis has also provided evidence to support TMR.  Because myocardial 
ischemia is primarily endocardial and typically not completely transmural, physiological 
redistribution of perfusion is more likely after TMR (Whittaker and Kloner 1997).  Experimental 
results from procedures using swine evaluated at longer time intervals showed a significant 
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improvement in perfusion lending further support to the angiogenesis hypothesis.  Human trials 
evaluating laser TMR have not shown perfusion improvements like those seen in animal studies, 
and currently there is no a sufficient explanation for this unfortunate difference. 
 
Cellular Cardiomyoplasty 
Cellular cardiomyoplasty is a procedure using cell transplantation to repair a damaged 
myocardium.  Previous studies have shown evidence that syngeneic myoblast implantation 
following a myocardial infarction will elicit improved ventricular function (Jain et al. 2001).  After 
years of investigation into the potential of using skeletal muscle cell grafting for cardiac repair, 
Menasche and his colleagues conducted the first clinical trial using skeletal myoblasts for MI 
repair eliciting encouraging results (Menasche et al. 2003).    
  
Satellite Cells: Identification and Significance 
 Kao and colleagues have been using autologous satellite cell implants from the skeletal 
muscle of dogs even prior to 1989 (Kao et al. 1989).  The satellite cells have been effectively 
harvested, labeled, and implanted into the injured heart to elicit new muscle formation and 
functional restoration (Jackson et al 2001). Other investigators have shown experimental results 
which support the implantation of autologous satellite cells from skeletal muscle as a potential 
approach for myocardial repair and functional improvement (Lash et al. 1957). 
 It is has been verified that unlike cardiac muscle, skeletal muscle maintains regenerative 
capabilities (Garrett and Best 1994). In 1961, Mauro first described the satellite cells of the 
skeletal muscle of a frog using electron microscopy. It is established that satellite cells play an 
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intricate part in skeletal muscle regeneration. The observance of the regenerative capabilities of 
satellite cells in skeletal muscle led researchers to consider the regenerative potential of 
myocardium (Marelli et al. 1992).  This consideration led to the realization that cardiac myocytes 
are terminally differentiated cells that lose their ability to undergo cell division at an early age (Li 
et al. 1996). 
Cellular cardiomyoplasty may prove to be more effective than coronary artery bypass graft 
and percutaneous coronary intervention therapies, which work to restore perfusion as well as to 
salvage dying muscle cells.  Cellular cardiomyoplasty works to replace the cells that are already 
dead or lost (Rumyantsev 1977). Even though recent clinical trials have shown encouraging signs 
for this innovative technique, more research is critical in the area of cellular cardiomyoplasty to 
further evaluate efficacy and to attempt to understand the mechanism(s) underlying this 
improvement. 
 
Satellite Cells: Muscle Repair 
 Over the years, it has become evident through the research of several investigators that 
satellite cell proliferation and induction are trauma-related (Schultz et al. 1978).  This same work 
has also shown that satellite cells elicit new myofiber formation through a process analogous to 
muscle histogenesis in the embryo. Following injury, muscle goes through an unambiguous 
progression of healing phases.  These healing phases include degeneration, inflammation, 
regeneration, and scar formation (Huard and Fu 2002).  Degeneration and inflammation have been 
noted during the first few days after injury.  Generally, regeneration begins approximately a week 
after injury and lasts up to a month at most, with peak performances noted at the two-week mark.  
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Fibrosis tends to begin between the 2nd and 3rd weeks following injury and continues to grow in 
size as time passes.  After only a few cell divisions, satellite cell progeny start to fuse forming 
multinucleated myotubes , but the continued growth of the myoblasts, though largely dependent 
on the degree of injury, can persist for up to approximately 10 days (Snow 1978).  
 Satellite cells are located between the external lamina and sarcolemma of skeletal muscle 
fibers, which can be seen in Figure 3 (Hawke and Garry 2004).  The presence of organelles such 
as ribosomes, rough endoplasmic reticulum, and golgi complexes implies the presence of 
metabolic activity in the satellite cells of immature muscle. This is in contrast to the low volume of 
such organelles found in adult muscle, which is indicative of a quiescent status. Investigators have 
previously shown that with the proper environmental signals, satellite cells enter into the cell cycle 
to provide the precursors necessary for new muscle formation in growth and repair (Jingbo and 
Liu 2004).  It is thought that the disruption of the basal lamina and plasma membrane after injury 
releases the activated satellite cells. 
 
Figure 3 Satellite Cell Location (adapted from Hawke and Garry 2001) 
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 The regeneration of skeletal muscle has been conveniently separated into four divisions: 
(1) satellite-cell activation; (2) myoblast or precursor proliferation; (3) differentiation; (4) return 
to quiescence.  Satellite-cell activation is the manner by which satellite cells exit G0 and enter the 
cell cycle (Hurme and Kallmo 1992).  The second stage in skeletal muscle regeneration is the 
proliferation of satellite cells and myogenic precursor cells.  Differentiation is the process whereby 
proliferating myoblasts derived from activated satellite cells and other myogenic precursors will 
withdraw from the cell cycle and either fuse to existing fibers in repair of damaged segments or to 
each other to form new fibers. Fusion events have been found to occur after cells exit mitosis and 
enter G1 (Hurme and Kallmo 1992). The ability of satellite cells to return to quiescence has been 
less thoroughly investigated than activation, proliferation, and regeneration. Under normal 
conditions the proportion of satellite cells that actually reside in G0 rather than in a long lag phase 
in G1 is not known, as are many important aspects of satellite-cell quiescence. For example, it is 
uncertain whether the same satellite cells that originally respond to an activating stimulus will 
return to quiescence, or whether the satellite cell compartment is only repopulated by daughter 
cells (Shutlz and McCormick 1994). 
Although the ability to identify satellite cells using histological methods will remain 
controversial until their characteristics and activities are further elucidated, it is recognized that 
the existence of multiple populations of myogenic precursor cells would allow muscle tissue to 
respond differentially to a particular stimulus, type of injury, or physiological demand, and thereby 
enable a highly controlled response (Rumyantsev 1991). The range of characteristics displayed by 
muscle precursor cells is most frequently made available through experimentation using the 
differences among cells isolated from muscle. For example, different lineages of muscle precursors 
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can be isolated from the variety of slow- and fast-twitch muscles in typical proportions, and each 
can differentiate to express distinct profiles of protein isoforms distinctive of slow and fast muscle.  
This justifies why the rectus abdominus skeletal muscle biopsy was used to isolate the satellite 
cells for this particular study involving myocardial regeneration.  To sustain the hearts workload, 
red muscle fibers which maintain slow fatigue characteristics are a practical selection for the repair 
of the cardiac muscle (Hawke and Garry 2001). 
 The basis for this procedure is to use the bodys natural repair process for skeletal muscle 
and extend this to the heart, because adult mammalian ventricular myocytes lack regenerative 
capability. Without intervention, scar formation is the final result of myocardial injury or damage.  
As long as scar is formed, complete regeneration of muscle tissue cannot occur, thus indicating 
that advances towards preventing muscle fibrosis as well as techniques to promote muscle 
regeneration must continue to be investigated. 
 The transplantation of satellite cells into an injured myocardium has resulted in improved 
myocardial function, but the mechanism of this improvement remains elusive (Kiortsis et al. 
1989).  Also, it still seems to be a topic of controversy concerning whether transplanted satellite 
cells differentiate into modified skeletal muscle fibers or into actual cardiac muscle cells, as once 
hypothesized, or if what has looked like transdifferentiation is actually cell fusion or 
contamination of the biopsy sample with unfamiliar progenitor cells and/or pluripotent cells that 
are stimulated to form new progenitor cells of a different tissue lineage (Young and Black 2004). 
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Rationale for Thesis 
 
 A significant amount of data has suggested that providing ischemic myocardium with 
angiogenesis through laser TMR leads to neovascularization and  to myocardial protection in the 
remodeling process after chronic myocardial ischemia.  Clinical observation and data have also 
demonstrated that a patients angina symptoms can be relieved within days after laser TMR 
treatment.  The neovascualrization developed through anigogenesis, however, does not occur 
immediately or even a few days after various laser, mechanical, or even pharmacological 
stimulation.  It takes at least weeks to develop new vessels in the ischemic myocardium after the 
expression angiogenic factors.  Does laser TMR provide an increase in regional perfusion 
following chronic ischemia? Is there a significant improvement observed in  cardiac function and 
scar formation following elicitation of cellular cardiomyoplasty and laser TMR therapies? Is there 
a greater improvement seen in global and regional contractility using two unconventional 
therapies in combination as compared to each therapy treating chronic myocardial ischemia 
individually? Based on these inquiries and relevant clinical research, evaluating the effectiveness of 
combining two unconventional therapies is the primary objective of this thesis. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
Materials 
 
 
Animals 
 
 Thirty miniswine, male and female, weighing 25-30kg were obtained from Harlan-Sinclair, 
Indianapolis, IN.     
 
Satellite Cells 
 
 Satellite cells were harvested from the rectus abdominus muscle at the lower chest portion 
of the miniswine after the completion of the first sternatomy procedure.  After isolating the cells 
and allowing them to plate on the flasks, the cells were then transfected and labeled using 
humanized green fluorescent protein from Renilla reniformis. (Stratagene Cloning Systems, La 
Jolla, CA). 
 
CO2 Heart Laser 
 
Transmyocardial Laser Revascularization (TLMR) was performed using an 800-W CO2 
laser (The Heart Laser, PLC Medical Systems, Milford, MA).  
 
Ameroid Constrictor 
 
 An ameroid constrictor was used to simulate the gradual constriction of the artery over 
time as coronary artery disease, inducing chronic ischemic damage (2.0mm ameroid constrictor, 
Research Instruments, SW, Escondido, CA). 
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Gortex Surgical Membrane 
 A semipermeable membrane made from expanded PolyTetraFluoroEthylene (PTFE) 
(Gore, Flagstaff, AZ). 
 
Media 
 
 * M-199 containing 1% antimycotic antibiotic solution (contains penicillin, streptomycin, 
and amphotericin B) purchased from Sigma Chemical Co., (St. Louis, MO) and 10% fetal bovine 
serum (Sigma Chemical Co., St. Louis, MO).  
 
* Hanks balanced salt solution lacking calcium and magnesium (Sigma) 
 
 
Enzymes 
 
Hyaluronidase (Sigma Chemical Co., St. Louis, MO) 
 
Collagenase (Sigma Chemical Co., St. Louis, MO) 
 
Trypsin containing EDTA (ATCC, Manassas, VA) 
 
 
Microspheres 
 
 Non-radioactive injectable, colored ultraspheres formulated as 10 million spheres/ml 
suspended in saline with Tween 80 & Thimerosal(E-Z Trac, Irvine CA). 
Syringe Pump 
 An infusion/ withdrawal pump, model # 906 (Harvard Bioscience Co., Holliston, MA),  
was used to obtain a reference blood sample for regional perfusion calculations with the 
microspheres. 
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Computer Program Hardware and Software 
2mm crystals (Sonometrics Co., London, ON, Canada) 
 
1mm crystals (Sonometrics Co., London, ON, Canada) 
 
LVP Millar model # MPC-500 (Millar Instruments Inc., Houston, TX) 
 
Arterial Millar model # SPC-350S (Millar Instruments Inc., Houston, TX) 
 
Cardiosoft Analysis Program version 3.2.4 (Sonometrics Co., London, ON, Canada) 
 
 
Methods 
 
 
Study Design 
 
A chronic ischemia myocardium swine model with an ameroid constrictor on the left 
anterior descending coronary artery was designed for laser TMR and cellular cardiomyoplasty to 
induce angiogenesis and myogenesis in order to improve regional blood flow along with overall 
cardiac function in ischemic myocardium.  The reasons for choosing this particular model wereas 
follows: 
1.  The larger animal model makes it technically more feasible to evaluate the functional study and 
to measure the regional blood flow. 
2.  Similar to humans, swine myocardium has little native collateral circulation 
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Experiment Time Line for In Vivo Study 
 
 
 
                                                                           9 weeks 
Ischemia                       I--------------------------------------------------------------------I 
        Group                         Baseline              Termination &  
                                                  - Placement of LAD                                                                                         heart extraction 
                                                    occluder- 
 
 
 
                                                 3   weeks                           6 weeks 
Ischemia + Laser           I-------------------I-----------------------------------------------I 
       Group                        Baseline                 TMLR  treatment                       Termination &  
                                                  -Placement of LAD             & plain media injection                                        heart extraction 
                                                     occluder- 
 
 
 
                                                 3   weeks                           6 weeks 
Ischemia + Laser           I------------------I------------------------------------------------I 
  + Cells Group           Baseline               TMLR  treatment                        Termination &  
                                                - Placement of LAD            & cells injection                                                    heart extraction 
                                                  occluder- 
 
 
                                                
      3   weeks                           6 weeks 
Ischemia + Cells           I------------------I------------------------------------------------I 
      Group                         Baseline             Cells injection                                    Termination &  
                                               - Placement of LAD                                                                                          heart extraction 
                                                  occluder- 
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Animals 
 
 Miniswine weighing 25 to 30 kg were purchased for the proposed study. The animals 
were housed in air-conditioned rooms with controlled light and dark cycles and  given free access 
to food and water at all times except when prepared for or under surgical procedures. After 
fasting overnight and receiving preoperative treatment, each pig was anesthetized with 8mg/kg 
telazol and 1mg/kg of xylazine following ear vein cannulation. The animals were intubated with a 
cuffed endotracheal tube following an injection of atropine (0.05mg/kg).  The surgical sites were 
shaved followed by a thorough cleaning with betadine.  A baseline electrocardiogram (EKG) was 
obtained using a 12-lead Hewlett Packard machine.  Also, the EKG was monitored throughout 
the procedure with leg leads.  Millar micro-tip pressure transducers were used to measure blood 
pressures.  Anesthesia was maintained with 1% to 2% halothane.  Humane care and proper 
analgesic, anesthetic, and tranquilizing drugs were provided to all experimental animals as needed.  
The  Principles of Laboratory Animal Care  and the  Guide for the care and use of Laboratory 
Animals were followed.  The proposed study was approved by the Animal Care and Use 
Committee of East Tennessee State University.  Thirty experimental animals were used for 
myocardial regeneration using cellular cardiomyoplasty and Laser Transmyocardial 
Revascularization. The animals were categorized into four groups: Group 1, Ischemia; Group 2, 
Ischemia + Laser TMR; Group 3, Ischemia + Laser TMR + Cells; Group 4, Ischemia + Cells.  
The same anesthetic regimen was used for each of the three different surgical procedures. 
Continuous electrocardiographic and blood pressure monitoring was used throughout each 
procedure to ensure a stable cardiac rhythm and pressure status. Antibiotics were administered 
postoperatively by a veterinary technician.  Also, pain medications were administered 
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intramuscularly following surgery as needed or until the normal activity level of the animal was 
resumed. 
 
Autologous Stem Cell Isolation, Cultivation, and Labeling 
 
 Skeletal muscle samples were obtained from the rectus abdominius (skeletal) muscle at the 
chest wall of the experimental animals during the first surgical procedure.  The muscle was rinsed 
with 70% ethanol followed by three rinses in Hanks balanced salt solution lacking calcium and 
magnesium but containing 1% antimycotic antibiotic solution (5ml of antibiotic added to 500ml 
M-199).  The tissue was minced and then incubated with 20 mL of enzyme solution (1% 
collagenase and 0.2% hyaluronidase).  After 10 minutes of incubation at 37ûC, the satellite cells 
were harvested by pouring the solution through  layers of sterile gauze into a sterile 50 mL 
centrifuge tube and pelleted by centrifugation.  The remaining tissue was incubated for 5 more 
minutes in enzyme solution to complete the release of satellite cells from the muscle.  The isolated 
satellite cells were washed three times with medium-199 containing serum (10% fetal bovine 
serum; 50ml added to 500ml of M-199) and 1% antibiotic antimycotic solution by centrifugation 
and then resuspended.   The cell number was counted using a hemocytometer.  After proper 
dilution, 1 X 106 cells were cultured with 8 mL of proliferation medium in a 25cm2 flask.  The 
isolated cells have a doubling time of approximately 22 hours.  They can easily go though 20 cell 
cycles and still retain their proliferation and differentiation properties.  Cells were generally 
labeled at 5-6 days after isolation when the cells were steadily growing and had adhered to the 
flask.  The cells were labeled via a viral tranfection method using humanized green fluorescent 
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protein from Renilla reniformis. This humanized green fluorescent protein was added (0.8mL per 
25cm2 flask) to the cells after removing the culture media. After a 3-hour incubation,  
enough media to cover the bottom of the culture flask was supplied to the cells. Twenty-four 
hours later the media was again replaced with fresh culture media. The fluorescence could be 
observed in the cells as early as 48 hours post transfection using a fluorescent microscope with a 
FITC filter. 
 
Myocardial Infarction 
 
 During the first surgical procedure following skeletal muscle biopsy of the chest wall and 
baseline recording measurements, the left anterior descending coronary artery was isolated and 
the ameroid constrictor was placed around the vessel. 
 
Cell Preparation for Implantation 
 
 After discarding the culture media, the satellite cells were rinsed with Hanks Balanced 
Salt Solution containing 1% antibiotic to removed any remaining serum that would prevent the 
cells from detaching. Next, the cells were incubated in a 5:1 dilution of plain Hanks Salt Solution 
containing Trypsin and ETDA. The detachment of the cells from the flask was observed via a light 
microscope and the cells were pelleted using centrifugation for five minutes and then were 
resuspended in 4mL of plain M-199 culture media.  The cell number was assessed using a 
hemocytomer. Cells were kept sterile and when needed were poured into a 5mL syringe and then 
injected into the injured myocardium. A representative aliquot of the cells were saved and allowed 
to continue their proliferation in a 25cm2 flask to observe the growth of mononucleated satellite 
cells into multinucleated myotubes. The reserved samples were fixed with buffered formaline and 
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kept in phosphate buffered saline until pictures could be captured using the fluorescent 
microscope with a FITC filter to observe the fluorescently labeled myotubes. 
 
Laser Transmyocardial Revascularization (TMR) 
 
 At 3 weeks after the initial operation while under sterile surgical preparation and following 
hemodynamic evaluation, the heart was exposed through a sternatomy.  Laser TMR was 
performed with an 800-W CO2 laser (The Heart Laser, PLC Medcial Systems, Milford, MA) 
using a single 20-J pulse timed to the R wave of the EKG; 20 channels were created at 1 cm 
intervals for the ischemic myocardium.  After laser TMR and the establishment of hemostasis,       
0.1mL of GFP labeled autologous satellite cells were injected at the center of each channel using a 
syringe with a 25G hypodermic needle. The laser TMR control animals were subjected to the 
same treatment but were injected with serum free culture medium. The carbon dioxide laser is 
timed from the R-wave of the EKG to allow a successful channel to be made with the laser 
instrument when the ventricle is blood-filled.  The two groups of miniswine not receiving satellite 
cell injections either received laser treatment followed by injections of plain culture medium into 
the channels or no laser treatment and no injection.  There also was a group of swine that received 
satellite cell injections into the ischemic myocardium without experiencing the heart laser 
treatment.  After closing the sternum and incision, the animals recovered in cages and received the 
same post-operative care and medication as at the time of the muscle biopsy and ameroid 
constrictor placement. 
 26
Hemodynamic Evaluation 
 The aortic and venous pressures were determined using Millar pressure transducers 
(Millar Instruments, Inc., Houston, TX).  The EKGs were recorded during each surgical 
procedure using a Hewlitt Packard electrocardiogram 12-lead machine.  The blood flow, 
contractility, systolic wall thickening, pressures, and EKGs were integrated using the 
computerized VF-1 hemodynamic system (Data Science Inc., St Paul, MN) and the Digital 
Sonomicrometer (Sonometrics Co., London, Canada).  Ultrasonic crystals were placed at the long 
axis of the heart (crystals1-2), the short axis of the heart (crystals 3-4), across the depth of the left 
ventricular free wall (crystals 3-5), and at the border of the ischemic area (crystals 6-7) (See 
Figure 4).  The cardiac output, pressure length loops, pressure volume loops, ejection fraction, 
and stroke work were used to determine the global and local contractile functions. 
 
Figure 4. Depicts sternatomy procedure of swine with crystals, constrictor, and pressure 
transducers labeled.1. aorta   2. apex   3. anterior   4. posterior (under the heart)  5. myocardial 
wall thickness 6. right infarct area    7. left infarct area ; LVP= left ventricular pressure transducer, 
AP= arterial pressure transducer, C= ameroid constrictor 
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Global Contractility 
 
 A way to assess the pumping function of a particular heart is to evaluate the work loops 
for that heart.  The work loop is derived for each heart beat in real time and is a graphic 
relationship between the changes in left ventricular pressure compared to the left ventricular  
volume during a single heart beat (See Figure 5).   The P-V loops were generated by 
simultaneously recording ventricular pressure and volume in the working heart. Ventricular 
pressure was obtained using an intra-ventricular pressure catheter.  Left ventricular volume was 
approximated by employing the equation for an ellipsoid, which is considered a well-established 
method.  By using a pair of crystals, one pair measuring the long axis (from the base to the apex) 
and the other pair measuring the short axis (on the equatorial posterior and anterior LV free wall), 
along with application of the ellipsoidal equation, the left ventricular volume was calculated per 
animal per cardiac cycle. 
 
Figure 5.  Pressure-Volume Loop illustration which allows LV function assessment. 
The left ventricular volume (LV V) comprises the x-axis and the left ventricular pressure 
(LVP) comprises the y-axis.  a. represents ventricular filling  b. represents isovolumetric 
contraction c. represents ventricular ejection d. represents isovolumetric relaxation SV= 
stroke volume, ESPVR= end-systolic pressure volume relationship, EDPVR= end-
diastolic pressure volume relationship, ESV= end-systolic volume, EDV= end-diastolic 
volume (Richard E. Klabunde, www.cvphysiology.com, 2005) 
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 Generating pressure-volume loops allows the assessment of myocardial compliance or 
commonly referred to as Emax. The Emax is the slope of the regression line that fits the end- 
systolic points on a pressure-volume loop after temporary occlusion of vena cava.  Cardiosoft 
determines these points by identifying the location in the cardiac cycle where the ration of 
instantaneous pressure to instantaneous volume, minus the volume axis intercept, is greatest.  
These points are located for all beats selected and used to calculate E-max.   
 
Cardiac Output Cardiac output is basically a flow rate that is directly related to the heart 
rate and stroke volume. Cardiac output is calculated on a beat-to-beat basis and the period is 
defined from end diastole to end systole. Cardiac output is a function of the end-diastolic volume. 
Cardiac output is expressed as the following equation: 
CO =  SV x  HR 
 
Ejection Fraction Ejection Fraction is the fraction of the end-diastolic volume ejected in 
each stroke.  Ejection Fraction is expressed as the following equation: 
 EF =  SV /  EDV  
 
Regional Contractility 
 
 As the heart contracts and relaxes, the cardiac muscle undergoes various changes in wall 
thickness and segmental shortening.  The magnitude of these changes can be affected by a variety 
of physiological and pathological processes.  Therefore, quantification of these changes provided 
valuable information concerning functionality and contractility.  Segment shortening percentages 
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express the changes in segment length between the minimum distance and end diastole.  Segment 
shortening is expressed as the following equation: 
SS%= [SL(ED)- SL(ES)] / SL (ED) 
 
 
Regional Perfusion 
 The colored microspheres prepared by E-Z TRAC were crosslinked polystyrene-
divinylbenzene microspheres. The method of animal preparation and microsphere injection with 
the E-Z TRAC colored microspheres were the same as that followed with radioactive 
microspheres in blood flow studies. To measure regional myocardial blood flow, the microspheres 
were injected into the left ventricle of the experimental animal during each surgical procedure just 
before chest closure. A line was placed into the left or right internal mammary artery, then a 2ml 
solution was injected into the heart (1.4 ml sucrose solution and 0.6 ml microspheres), followed 
by a reference blood sample collection at a rate of 15 ml/min for one minute with a syringe pump.  
The reference blood sample was placed into a 50ml centrifuge tube with 0.1ml of heparin, labeled 
with the pig identification number and date, and then blood reagent solution from E-Z TRAC was 
added (see Figure 6).  Once injected, the E-Z TRAC colored microspheres then mixed with the 
arterial blood, distributed to the tissue, and ultimately lodged in the microvasculature. The number 
of microspheres in the myocardial tissue of interest and in reference blood sample were 
determined by following an extraction procedure using reagents and instructions supplied by E-Z 
TRAC. After completing the process to retrieve the microspheres from the reference blood 
sample or from the myocardial tissue, the spheres were counted using a hemocytometer. 
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Figure 6.  Microsphere Retrieval Process (Stason Pharmaceuticals [Internet]. Irvine, CA:  
Interactive Medical Technologies; 2004 Sept. 10; Adapted from: http://www.stason.com/). 
 
 
Statistical Analysis 
 
 A one-way ANOVA statistical test from Excel was used to compare the means among the 
groups. Also, a non-parametric analysis, Kruskal-Wallis, with minitab software was used. A t-test 
was used to assess the differences of the calculated values for each group of hearts at each time 
point as compared to the group receiving only a coronary occlusion termed as Ischemia Group. 
P<0.05 was considered significant in all statistical tests. This method of statistical  
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analysis was used to assess statistical significance for all cardiac function values evaluated in this 
project. 
 
Heart Harvest 
 
 The animals were deeply anesthetized with halothane. The chest cavity was opened 
exposing the heart. The heart was removed from the chest cavity, rinsed with 0.9% saline solution 
and placed in a labeled, sealed bag to be frozen in order to section. Additionally, the animals were 
heparanized prior to organ harvest, which inhibited blood clotting and enabled better tissue 
cleanup.   
 
Heart Sectioning 
 
 The heart was sectioned into 0.2 cm slices using a toastmaster platinum electric food 
slicer.  The tissue was then placed in iced buffered formaline.  The heart tissue sections were then 
processed, paraffin embedded, and sectioned by James H. Quillens pathology departments 
histology technician. 
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CHAPTER 3 
RESULTS 
 
 
 Isolation of Satellite Cells from the Skeletal Muscle of Miniswine 
 Light microscopy allowed morphological evaluation of the satellite cells.  Figure 7 
illustrates that in this experiment, satellite cell isolation, proliferation, and labeling were 
successfully completed. Panel d of Figure 7 shows the formation of the satellite cells into 
multinucleated myotubes and the presence of the fluorescence in the myotubes as well. 
 
 
  
 
Figure 7. Light Microscopy Pictures of Swine satellite Cells a) early culture of passage 1 cells in 
20% fetal bovine serum (FBS)  b) early culture of cells with green fluorescent protein (GFP) label 
c) formation of multinucleated myotubes from mononucleated cells d) multinucleated myotubes 
with GFP label. 
 
Cell Counts 
 
 No correlation could be made between number of injected cells and functional 
improvement.  However, this element of cellular cardiomyoplasty remains elusive despite the avid 
interest in the question that remains: Is there a minimal or maximal cell implantation number 
a b
c d
 33
necessary to have beneficial effects?  In addition, the range of cells implanted in this experiment is 
too close (1.3 X 106 to 6.5 X 106 cells) to have a meaningful evaluation for cell number and 
functional recovery. 
 
Pathological Evaluations 
 
 Sectioning the pig hearts allowed us to visualize the scar portion versus the area of viable 
myocardium.  Figure 8 illustrates the method used in sectioning the hearts. Pictures were taken of 
these sections using a digital camera which allowed transference of this information into an 
imaging program (See Figure 9). The imaging software made the scar area percentage calculation 
possible through freehand visualization and interpretation. The chart (See Figure 10) shows the 
percentages of scar area per group.  A significant decrease in the scar area was found for the 
ischemia + laser + cell group. 
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Figure 8. Illustration of how the swine hearts were sectioned: C designated control region and (i) 
designated the ischemic regionof the myocardium assigning two (1 & 3) of the tissue sections for 
digestion for microsphere counts and two to be frozen (2 & 4) to be used for pathological 
evaluation  
 
 
 
Figure 9. Representative Heart Sections from each Animal Group A) Ischemia B) Ischemia + 
Laser C) Ischemia + Laser + Cells D) Ischemia + Cells. Morphological evaluation of these heart 
sections allows for the observation and comparison of the left ventricle (LV) scar area. 
1
2
3 
4
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Figure 10. Graphical Representation of Scar Area Differences 
Heart sections from different groups and percent scar area differences; black bars indicate SEM 
values; * represents a significant reduction in scar area in the TMR +cell and cell groups from the 
ischemia group. Significance was assessed using a 1-way ANOVA (p<0.05). 
 
 
Electrocardiograms 
 
 During the cardiac cycle, the electrical event precedes the mechanical.  The 
electrocardiogram (ECG or EKG) is the standard clinical tool used to evaluate the electrical 
activity of the heart non-invasively.  It is a graphic record of the sum of the cardiac action 
potentials from different regions of the heart that can be picked up by recording electrodes from 
the surface of the body as potential differences or voltage differences.  These differences are 
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recordable because of the timing and sequence of depolarization and repolarization of the heart.  
Assessment of the height of various waveforms and the duration of the waveforms and their 
various components allows insight into the normalcy or pathology of the electrical nature of the 
heart. The electrocardiogram shown below (Figure 11) illustrates that what was seen in the pig 
recordings at baseline (a normal sinus rhythm) and what was observed following LAD occlusion 
(ST segment elevation indicative of myocardial injury).  
 
 
 
Figure 11 Electrocardiogram showing lead II in both panels: A) Normal Sinus Rhythm of minipig 
heart B) ST elevation & fibrillation (6th beat) after ischemic injury  
 
 
 
 
 
 
 
A 
B 
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Hemodynamic Evaluations 
 
 The contractility and functionality of these hearts were evaluated in each pig at two 
distinct but consistent time points. The measurements of the heart that enable the evaluation of the 
function each heart were recorded using ultrasonic crystals attached at seven points on the heart 
(discussed in more detail in the Materials and Methods section).  These measurements were 
obtained at a baseline value, before any treatment was elicited, and again just before termination, 
nine weeks after the initial normal recordings.  In comparing the different components of 
function, the baseline value for each animal was designated as 100%. For each animal cardiac 
output, segment-shortening, ejection fraction, and E-max were evaluated during each of the 
surgeries. Measurements of hemodynamic parameters using 1-way ANOVA, t-tests, and Kruskal-
Wallis comparisons revealed no statistically significant differences (P=ns). 
 
Cardiac Output 
 
 Cardiac Output is directly related to the stroke volume and heart rate. We evaluated 
cardiac output for each group and expressed the values by assigning the recorded baseline 
measurement as 100% as compared to the value obtained during the termination procedure. As 
expected, two of the treatment groups, ischemia + laser and ischemia + laser + cells, showed clear 
increase, though not statistically significant,  in cardiac output as compared to the control 
ischemic group. However, an unexpected result was the low output percentage values of the 
group receiving ischemia + cells. The graph (Figure 12) represents the cardiac output percentages 
for each of the four categories of animals. There was no significant difference observed in cardiac 
output among the experimental groups, though there was a general observable trend that would 
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require further research in order to determine whether the differences would reveal significance 
using larger population samples as well as evaluating the animals progression at longer time 
points. 
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Figure 12. Graphical Representation of Cardiac Output: SEM indicated by black bar lines; 
Significance was assessed using 1-way ANOVA. No significant statistical difference was found 
among the groups (p=ns). 
 
 
Ejection Fraction 
 
 Ejection Fraction is another assessment of global contractility and it is the ratio of the 
stroke volume to the end-diastolic volume. There is no significant difference among the groups 
(Figure 13).  These values differ only modestly and revealed no significant functional difference in 
the ejection fraction percentages using the baseline values as 100% across the groups. 
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Figure 13.  Graphical Representation of Ejection Fraction: SEM indicated by black bar lines. 
Significance was assessed using 1-way ANOVA where no statistical significance was found 
(p=ns). 
 
 
Segment Shortening 
 
 Percent myocardial shortening in the LAD region is demonstrated below in Figure 14. The 
SS% of the remote myocardium did not reveal differences among the first three groups. However, 
there was a significant reduction of the regional contractility in the ischemia + cells group as 
compared to the ischemia + laser group (p<.05).  This was attributed this to the inflammatory 
response as a result of the Gortex membrane used as a synthetic pericardium in an effort to reduce 
adhesion formation seen in greater than 50% of the pigs from this particular group. Also, there 
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was noticeable reduction in regional contractility of the other two groups as compared to the 
ischemia + laser group.   
Segment Shortening (6-7)
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     Figure 14.  Graphical Representation of Segment Shortenin: SEM indicated by black bar lines 
                             denotes significant difference between the ischemia + cells group as  
compared to ischemia + laser group (p<0.05). Significance was assessed using 1-
way ANOVA followed by a t-test comparison. 
 
            
Pressure-Volume Loops 
 
 A single left ventricular cycle of contraction, ejection, relaxation, and refilling can be 
visualized using a pressure-volume loop. The pressure volume loops were generated by 
simultaneously measuring the left ventricle using a pressure catheter and by evaluating the volume 
of the left ventricle using the ultrasonic crystals.  Several factors can elicit a alteration in the 
pressure-volume loop from its baseline (normal) form.  The stroke volume is the volume of blood 
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ejected from the ventricle on each heart beat and can be estimated using the pressure-volume 
loops by subtracting the end-systolic volume from the end-diastolic volume.  There was no 
significant difference in stroke volume values among the groups (See Figure 15). The following 
chart (See Table 1) lists the stroke volume (SV) values calculated for each animal of each animal 
group category.  The highlighted selection from each group was chosen using the average value 
obtained for each animal group.  Each highlighted animal was then used to create the 
representative loops (See Figures 16-19) from each categorical group to observe what was 
occurring during the cycle of the heart through the use of pressure-volume loops. 
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Figure 15.  Graphical Representation of Stroke Volume: SEM indicated by black bar lines 
         denotes significant difference between the ischemia + cells group as compared to ischemia + 
laser group (p<0.05). Significance was assessed using 1-way ANOVA, followed by t-test 
comparison. 
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Table 1. Stroke Volume Values and Averages per Animal and per Animal Group  
The stroke volume values for each animal of each group and mean values for each group at 
baseline and at sacrifice time points are listed. 
 
          Stroke Volume   
     
     
 Control  Baseline   Sacrifice 
2015  27  30 
3018  31  20 
3023  24.8  29.9 
3028  18.5   30 
 Mean= 25.325  27.475 
     
Laser     
3003  28  27 
3005  12  28 
3008  26  36.2 
3021  16.6  27 
4008  53  15 
 Mean= 26.9   26.55 
Laser + 
Cells     
2016  27.9  39.5 
2017  16.3  19.4 
2018  32.3  15.3 
2019  12.1  16.3 
3004  19  28 
3009  37  19 
3010  13.3  38.8 
 Mean= 22.557   25.525 
     
Cells     
3019  25.4  17 
3022  29.1  11.9 
4018  27.9  11 
4019  22.5  40.4 
 Mean= 26.225   20.075 
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Figure 16. Representative p-v loops from the ischemia only animal group at baseline and sacrifice 
time points. From Baseline to sacrifice, these Pressure-Volume (PV) loops show a marked 
increase in the left ventricular volume, a stroke volume of approximate equal proportions and no 
real change in the overall left ventricular pressure.  However, both the end-diastolic and end-
systolic volume increased a substantial amount.   
 
Figure 17. Representative p-v loops from the ischemia + laser animal group at baseline and 
sacrifice time points. In the representative loops from the Ischemia + Laser group, there was no a 
great change in the overall left ventricular pressure or in the left ventricular volume from baseline 
to sacrifice.  The end-systolic volume and end-diastolic volume did decrease slightly but the 
stroke volume remained relatively the same. 
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Figure 18. Representative p-v loops from the ischemia +  laser + cells animal group at baseline 
and sacrifice time points. From baseline to sacrifice, the ischemia + laser + cells representative 
loops illustrated a rather large shift in left ventricular volume but the left ventricular pressure 
remained relatively the same.  The end-systolic and end-diastolic volumes dropped an observable 
amount with only a slightly noticeable decrease in stroke volume.   
 
 
Figure 19. Representative p-v loops from the ischemia + cells animal group at baseline and 
sacrifice time points.  In the ischemia + cells representative loops, there were observable increases 
in left ventricular volume and pressure.  The end-systolic and end-diastolic values both increased 
but the overall stroke volume and stroke work decreased relatively. 
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 An increase in stroke volume is the result of an increase in end-diastolic volume, which is 
the result of increased venous return (effects of changes in preload).  The increase in stroke 
volume is reflected in increased width of the pressure-volume (p-v) loop.  The p-v loops that 
indicated a decrease in stroke volume reflected the change with a decrease in the width of the p-v 
loops.  The decrease in stroke volume results in a decrease in end-systolic volume. In general, all 
the loops show a decrease, in some cases very slight, in pressure from the normal or baseline 
pressure-volume loop which can be viewed as a loss in height of the loop and correlates with 
decreased contractility from baseline for each of the categories. 
As mentioned, the slope of the line through the points at the end of the systole represents 
the end-systolic pressure-volume relation (ESPVR) and is often used as an index of contractility. 
Therefore, the slope remains unchanged without any accompanying changes in contractility even 
with changes in preload or afterload. The slope of the line of the ESPVR for each loop for each 
subject were compared and averaged across the groups using the baseline value as normal, or 
100% (See Table 2).   Again, there were no statistically significant differences among the groups 
that were evaluated using 1-way ANOVA statistical analysis tests, accepting significance as a p-
value less than 0.05.   
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Table 2. Load Variables and Averages per Animal and per Animal Group:  Emax, EDPVR 
(End-diastolic Pressure-Volume Relationship), & PRSW (Preload Recruitable Stroke Work) for 
each group and the mean value per group. A 1-way ANOVA comparison of the means among the 
groups reveals no significance (p=ns). 
  Load Variables   
  
(values @ 
sacrifice)   
         
  Emax EDPVR PRSW 
     
     
Ischemia 2015 0.859 0.192 0.464 
 3018 0.940 0.876 0.974 
 3023 0.899 0.840 0.948 
 3028 0.970 0.831 0.966 
 Mean 0.917 0.6847 0.838 
     
     
I + Laser 3003 0.996 0.610 0.984 
 3005 0.987 0.814 0.977 
 3008 0.994 0.763 0.976 
 3021 0.985 0.909 0.983 
 4008 0.988 0.776 0.981 
 Mean 0.989 0.815 0.979 
     
     
I + L+ Cells 2016 0.983 0.831 0.976 
 2017 0.971 0.810 0.420 
 2019 0.511 0.101 0.869 
 3004 0.995 0.926 0.990 
 3009 0.934 0.915 0.538 
 3010 0.983 0.489 0.965 
 Mean 0.856 0.608 0.841 
      
     
I + Cells 3019 0.470 0.288 0.597 
 3022 0.989 0.558 0.204 
 4018 0.998 0.658 0.623 
 4019 0.927 0.487 0.757 
 Mean 0.846 0.498 0.545 
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Regional Perfusion 
 The microspheres were used to compare regional perfusion as a result of angiogenesis or 
lack thereof in each of the randomly assigned groups (See Table 3).  There were only very slight 
differences in the flow per gram per milliliter between the groups.  
 
Table 3. Microsphere Counts to Measure Regional Perfusion. Represents microsphere counts 
from the ischemic region of the myocardium per animal group category: LAD= left anterior 
descending coronary artery; N= number of animals per group for regional perfusion analysis  
 
  Regional Myocardial blood flow (ml/100g/min)   
      9 weeks post ameroid constrictor placement     
      Ischemia Laser Laser +Cells Cells     
  LAD region   44 46 48 42     
  N   3 4 3 3     
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CHAPTER 4 
 
DISCUSSION 
 
 Miniswine satellite cells were harvested and labeled successfully.  Pathological evaluations 
revealed significant scar area reductions in the cell + laser TMR and the cell groups.  This exciting 
result was puzzling because the hemodynamic analysis, which evaluated cardiac function, resulted 
in no supporting functional improvement, specifically in the laser TMR + cells group.  However, 
since this loop was only a representative and did not include the entire group, its seemed 
overreaching o use it to make any concrete claims, especially when considering the results of the 
other functional parameters. In the laser TMR + cells group, the left ventricular volume was 
decreased while maintaining cardiac output.  The ischemia representative loop showed an increase 
in left ventricular volume with a decreased cardiac output which together are indicative of a 
failing heart. For all of the animal groups a 50% reduction was observed in the ejection fraction 
values, which is not atypical following myocardial ischemia, however, it would seem worthwhile 
to evaluate the ejection fraction at greater time intervals.   
 Autologous stem cell therapy has been shown to induce regeneration of viable 
myocardium (Chiu et al. 1995).  The mechanism behind this phenomena has yet to be elucidated 
(Jingbo et al. 2004).  According to the American Heart Association, cardiovascular disease (CD) 
remains the number one killer of men and women in the United States.  It was hypothesized that a 
combination therapy using transmyocardial laser revascularization in addition to cellular 
cardiomyoplasty would elicit angiogenesis and myogenesis in a chronic ischemic heart.  The aim 
of our study was to evaluate the effectiveness of combining these two therapeutic techniques 
(Horvath et al. 2001).   
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Laser TMR is FDA approved and has been used to treat patients suffering from chest pain 
who do not otherwise qualify as participants in other traditional revascularization techniques.  
However, previous studies in the CD literature have shown that autologous stem cell implantation 
following ischemic injury results in improved ventricular function.  (Jain et al.)  However, whether 
or not the implantation of satellite cells improves cardiac function has yet to be confirmed 
(Wozniak et al. 2004). Based on these results, it is impossible to confirm or reject this implication 
and therefore, no further insight has been gained into the mechanism behind the regeneration 
phenomena. The lack of biochemical markers for satellite cells has made isolating a pure 
population of these cells and the identification of these cells after implantation quite challenging.  
For many years, the goal of advancing myocardial neovascularization has been studied in hopes of 
providing an alternative therapy to those patients who cannot undergo conventional 
revascularization (Yoon, Kao and Magovern 1995).  Still, many questions surrounding this topic 
remain:  If there is an improvement seen following satellite cell implantation, what is the 
mechanism? Once these cells are implanted into the injured myocardium, where do they go or 
what do they become? Is there a best way to administer the implantation of the cells and is there a 
necessary number of cells needed for implantation?  
 Over approximately the last 40 years, numerous experimental studies have been performed 
to investigate the revascularization potential of transmyocardial revascularization and the possible 
working mechanism underlying the observed clinical improvement in angina pectoris after this 
treatment (Menno et al  2002).  An acceptable explanation for this clinically observed relief has 
not been found.  Over the years, a number of hypotheses have been used to explain the 
effectiveness seen with transmyocardial revascularization therapy.  The patent channel 
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philosophy has been somewhat recently dismissed as a possibility and has left angiogenesis and 
denervation hypotheses competing for the final answer.  However, since supportive evidence 
has been presented which gives credit to both proposed mechanisms, it can be deduced that 
perhaps both play a role in this phenomena.  It is apparent that more clinical studies and further 
research must be conducted in order to obtain a clearer understanding of the mechanism behind 
laser TMR as well as to optimize the delivery of the therapy in general. 
 Implantation of autologous skeletal myoblasts (satellite cells) as an approach for 
myocardial repair and functional improvement has been confirmed by other researchers (Bischoff 
1994).   The benefits of employing autologous satellite cells are further supported by more recent 
publication and encouraging preliminary clinical evaluation by Kao and colleagues as well as 
others (Jackson et al 2001). If favorable observations can be confirmed by rigorous clinical trials, 
cellular cardiomyoplasty using autologous satellite cells may offer a new treatment.  Although the 
present study does not directly correlate with other findings, we believe that the introduction of an 
additional unexpected inflammatory response from the Gortex membrane used as a synthetic 
pericardium in an attempt to reduce adhesion formation may have greatly skewed the results for 
the ischemia + cells group.   
 Regional myocardial blood flow analysis of this study indicated that relative blood flow 
across the groups was not significantly different. Further research is needed to confirm this 
observation because the population size may not have been large enough to fairly assess 
significance between groups.   There is little experimental information in the literature as to 
whether transmyocardial laser revascularization improves long-term transmural perfusion and left 
ventricular function in chronically ischemic myocardium.  In a long-term study conducted by 
Hughes and coworkers, regional contractility and perfusion were found to improve  
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(Hughes 1999).  Horvath and colleagues demonstrated an improved regional contractility at rest 
in a chronic porcine model of myocardial ischemia, six weeks after transmyocardial laser 
revascularization treatment (Horvath 1997).  However, in contrast, Kohmoto and associates 
measured regional myocardial blood flow using colored microspheres in an acute ischemic canine 
model observing no significant differences in regional blood flow, which is consistent with these 
results (Kohmoto et al 1998).  Lutter and colleagues found that while CO2 laser 
revascularization may have an effect on microperfusion and regional contractility when under 
stress, compared to their ischemia group of animals three months post chronic myocardial 
ischemia, they found little to no effect on overall perfusion and global left ventricular function 
(Lutter and Yoshitake 1998). 
 In his recent seminar on tissue engineering, Nerem (2005) stated that many of the 
therapies of the 21st century will be of a combination nature.  Our experiment to evaluate the 
effectiveness of combining two therapies for cardiovascular disease corresponds to  Nerems 
prediction, but the results have left us asking the question: What can explain what we found 
hemodynamically versus what we observed morphologically? Could it be that even though to the 
naked eye the gross heart sections clearly showed less scar tissue and greater amounts of muscle 
formation, these morphological improvements do not transfer into physiologic functional 
improvements? Or could it be that the morphological differences are the first in a series of 
improvements to be observed?   In evaluating cardiac function using the transducing sonometric 
crystals, we believe that the result of no statistically significant differences for each hemodynamic 
aspect evaluated can be attributed to a number of factors/limitations.  
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Limitations 
  Halothane was used as the inhalation agent in the anesthetic machine to maintain the 
animals sedation throughout the surgical procedures.  Even though halothane has been used 
extensively for anesthesia in swine, it has been shown to induce generalized cardiovascular 
depression and on occasion even elicit bradycardia (Tranquilli et al 1983).  These actions are 
manifested as lowered cardiac output and stroke volume values.  The decrease in cardiac output is 
associated with decreased left ventricular function (Duke et al. 1977).  Even though we believe 
the use of halothane as the anesthetic agent for this experiment could have had negative affects, 
the fact that halothane was used for all the animals in all surgical procedures ensures equality for 
comparisons among the groups.   
 Another limitation that could have influenced our findings was the small population used 
for this experiment.  Miniswine used for research purposed are costly animals to purchase, 
maintain, and medicate.  The sample size is a critical element of an experiment in order to ensure 
enough study subjects to enable the detection of anticipated effects while determining the 
minimum sample size required to do so. 
 Thirdly, the timescale for this experiment could have been too short.  For the short 
duration, the heart will compensate after ischemic injury; for example, a decrease in stroke volume 
could be compensated by an increase in heart rate to maintain adequate cardiac output to sustain 
the animal.  However, over the long term, compensatory abilities will begin to fail, yielding 
perhaps a more accurate assessment of the selected therapies.     
 Also, despite the fact that swine have been shown in investigative literature to be the 
animal of choice, or at least one of them, in experiments such as this where redo open-chest 
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procedures are required, these animals are challenging specimens (Sanders et al. 1977).  The 
fibrotic adhesions, which were unexpected, were extremely challenging to separate from the 
pericardium to even be able to proceed with analysis. Additionally, without sedation the miniswine 
do not easily tolerate typical monitoring methods, such as obtaining blood pressure, heart rate, 
and temperature values.  
Conclusion 
 To date, perhaps the most successful therapy used for cardiovascular disease is a heart 
transplant.  Unfortunately, the demand is increasing while the supply is not.  Although our results 
were not as we would have predicted, from aspects and observable trends in our data as well as 
findings in other literature, we believe that the fusion of the proven benefits of medical device 
technology, such as the CO2 heart laser in providing site-specific therapy with the pluripotent 
attributes of emerging biologic therapeutics, and satellite cell implantation, creates tremendous 
opportunity for revolutionary change in the way we view and treat disease.  Further research, 
perhaps using larger populations and longer-time intervals, will need to be conducted to discern 
why such a static difference was observed between morphology and function. 
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